• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

    2/9/23 11:19:19 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email
    SC 13G/A 1 tv0869-exactsciencescorp.htm SCHEDULE 13G/A exactsciencescorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Exact Sciences Corp.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  30063P105

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  30063P105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    129,020

    7.  SOLE DISPOSITIVE POWER

    16,868,861

    8.  SHARED DISPOSITIVE POWER

    383,604

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    17,252,465

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.71%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Exact Sciences Corp.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5505 Endeavor Lane
    Madison, WI 53719

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    30063P105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $EXAS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    More analyst ratings

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Doyle James Edward sold $62,400 worth of shares (1,485 units at $42.02), decreasing direct ownership by 2% to 59,962 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    8/14/25 4:30:16 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, GM, Precision Oncology Baranick Brian converted options into 5,350 shares and covered exercise/tax liability with 2,717 shares, increasing direct ownership by 12% to 25,226 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    8/7/25 5:30:03 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, GM, Screening Orville Jacob A converted options into 5,350 shares and covered exercise/tax liability with 2,515 shares, increasing direct ownership by 11% to 28,237 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    8/7/25 5:30:05 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Announces Second Quarter 2025 Results

    Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

    Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

    Cologuard Plus™ Available In-Network August 2025 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximately 5.8 million Medicare Advantage members. "The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more

    7/31/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    SEC Filings

    View All

    SEC Form 10-Q filed by Exact Sciences Corporation

    10-Q - EXACT SCIENCES CORP (0001124140) (Filer)

    8/6/25 5:07:45 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - EXACT SCIENCES CORP (0001124140) (Filer)

    8/6/25 4:08:50 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Exact Sciences Corporation

    S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)

    7/11/25 4:06:24 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Exact Sciences with a new price target

    Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

    4/10/25 12:41:36 PM ET
    $EXAS
    Medical Specialities
    Health Care

    RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

    RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

    3/13/25 7:36:02 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Barclays initiated coverage on Exact Sciences with a new price target

    Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00

    1/23/25 7:42:29 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology

    Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

    Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl

    7/25/24 8:00:00 AM ET
    $EXAS
    $PODD
    Medical Specialities
    Health Care
    Medical/Dental Instruments

    $EXAS
    Financials

    Live finance-specific insights

    View All

    Exact Sciences Announces Second Quarter 2025 Results

    Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

    Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Schedules Second Quarter 2025 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, d

    7/14/25 6:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    10/7/24 11:37:08 AM ET
    $EXAS
    Medical Specialities
    Health Care